

2021/02/14

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 219620US0CONT

First Inventor or Application Identifier Tadaki KAGAWA

Title BENZAMIDINE DERIVATIVES

Assignee Name: Ajinomoto Co., Inc.

Assignee Address: 15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-0031 Japan

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

Assistant Commissioner for Patents
ADDRESS TO: Box Patent Application
Washington, DC 20231

1. Fee Transmittal Form (e.g. PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Specification Total Sheets 160
3. Drawing(s) (35 U.S.C. 113) Total Sheets
4. Oath or Declaration Total Pages 5
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 C.F.R. §1.63(d))
(for continuation/divisional with box 17 completed)
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §1.63(d)(2) and 1.33(b).
5. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. Computer Readable Form (CRF)
 - b. Specification or Sequence Listing on :
 - i. CD-ROM or CD-R (2 copies); or
 - ii. Paper
 - c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (cover sheet & document(s))
8. Application Data Sheet. See 37 CFR 1.76
9. 37 C.F.R. §3.73(b) Statement
(when there is an assignee) Power of Attorney
10. English Translation Document (if applicable)
11. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
12. Preliminary Amendment with marked-up copy
13. White Advance Serial No. Postcard
14. Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. Applicant claims small entity status.
See 37 CFR 1.27
16. Other: Request for Priority

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below:

 Continuation Divisional Continuation-in-part (CIP) of prior application no.: 09/731,729

Prior application information: Examiner: TRUONG

Group Art Unit: 1624

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

18. Amend the specification by inserting before the first line the sentence:

 This application is a Continuation Division Continuation-in-part (CIP)

Sub C1 of application Serial No. 09/731,729 Filed on December 8, 2000, now allowed which is a Continuation application of International Application Number PCT/JP99/03055, filed June 8, 1999.

 Which was published in English Which was not published in English This application claims priority of provisional application Serial No.

Filed

19. CORRESPONDENCE ADDRESS



22850

(703) 413-3000

FACSIMILE: (703) 413-2220

Name: Norman F. Oblon	Registration No.: 24,618
Signature:	Date: <i>July 14, 2002</i>
Name: William E. Beaumont	Registration No.: 30,996

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Tadakiyo NAKAGAWA, et al.

GAU:

SERIAL NO: NEW APPLICATION

EXAMINER:

FILED: HEREWITH

FOR: BENZAMIDINE DERIVATIVES

REQUEST FOR PRIORITY

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

J1002 U.S. PTO
10/07/3985
02/14/02



SIR:

Full benefit of the filing date of U.S. Application Serial Number 09/731,729, filed DECEMBER 8, 2000, is claimed pursuant to the provisions of 35 U.S.C. §120.

Full benefit of the filing date of U.S. Provisional Application Serial Number , filed , is claimed pursuant to the provisions of 35 U.S.C. §119(e).

Applicants claim any right to priority from any earlier filed applications to which they may be entitled pursuant to the provisions of 35 U.S.C. §119, as noted below.

In the matter of the above-identified application for patent, notice is hereby given that the applicants claim as priority:

COUNTRY	APPLICATION NUMBER	MONTH/DAY/YEAR
Japan	10-159627	June 8, 1998
Japan	10-159628	June 8, 1998
WIPO	PCT/JP99/03055	June 8, 1999

Certified copies of the corresponding Convention Application(s)

are submitted herewith

will be submitted prior to payment of the Final Fee


were filed in prior application Serial No. 09/731,729 filed DECEMBER 8, 2000.

were submitted to the International Bureau in PCT Application Number
Receipt of the certified copies by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.

(A) Application Serial No.(s) were filed in prior application Serial No. filed ; and

(B) Application Serial No.(s)
 are submitted herewith
 will be submitted prior to payment of the Final Fee

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon

Registration No. 24,618

William E. Beaumont
Registration No. 30,996

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/98)

Docket No. 219620US0CONT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR(S) Tadakiyo NAKAGAWA, et al.

SERIAL NO: New Application

FILING DATE: Herewith

FOR: BENZAMIDINE DERIVATIVES

FEE TRANSMITTALASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	1 - 20 =	0	× \$18 =	\$0.00
INDEPENDENT CLAIMS	1 - 3 =	0	× \$84 =	\$0.00
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS (If applicable)			+ \$280 =	\$0.00
<input type="checkbox"/> LATE FILING OF DECLARATION			+ \$130 =	\$0.00
			BASIC FEE	\$740.00
			TOTAL OF ABOVE CALCULATIONS	\$740.00
<input type="checkbox"/> REDUCTION BY 50% FOR FILING BY SMALL ENTITY				\$0.00
<input type="checkbox"/> FILING IN NON-ENGLISH LANGUAGE			+ \$130 =	\$0.00
<input type="checkbox"/> RECORDATION OF ASSIGNMENT			+ \$40 =	\$0.00
			TOTAL	\$740.00

Please charge Deposit Account No. 15-0030 in the amount of \$0.00 A duplicate copy of this sheet is enclosed.

A check in the amount of \$740.00 to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.Date: February 14, 2002

Norman F. Oblon

Registration No. 24,618



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/01)William E. Beaumont
Registration No. 30,996